Japan Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Japan Pharmaceuticals and Healthcare Report Q3 2013 May 15th 2013, 00:00 BMI View: Japan remains the most attractive market in the Asia Pacific, due to the ageing and affluent population and strong regulatory conditions. In particular, we highlight that the slowing economy poses opportunities for generic drug players looking to expand in the country. Meanwhile, domestic firms will continue to expand overseas (especially in emerging markets) in order to maintain revenue growth. Headline Expenditure Projections ? Pharmaceuticals: JPY10,358bn (US$129.7) in 2012 to JPY10,823bn (US$118.9bn) in 2013; +4.5% in local currency terms and -8.3% in US dollar terms. Forecast broadly in line with Q213, US growth down due to currency fluctuations. ? … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=96073. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/japan-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions